Shots:

• The US FDA has approved an expanded indication for CardioMEMS HF System to support the patients care living with HF & for patients who undergo a blood test showed elevated levels of biomarkers that indicate worsening HF
• The approval was based on data on the (GUIDE-HF) trial in 3600 patients at 118 centers in North America which showed a 19% reduction in composite EPs of all-cause mortality & total heart failure events, 28% reduction in HF hospitalizations & improved care for patients with HF
• The CardioMEMS HF System is a small implantable sensor & a paperclip-sized device that placed in the pulmonary artery during an MIS, monitors for pressure changes indicating worsening HF

 Ref: PR Newswire | Image: APK Pure